The Triple Negative Foundation has an excellent overview of research presented at the annual meeting of the American Society for Clinical Oncology (ASCO) June 2 through 7, 2011. While several studies dealt with TNBC, none was groundbreaking. According to the Foundation:
This year, according to TNBCF Medical Advisory Board Member, Eric Winer, MD, there was no study presented on TNBC that represents a major step forward or will have a significant immediate impact on clinical practice. That statement is true for the meeting as a whole in which the majority of studies were focused on incremental advances, especially in the area of targeted therapies.